Disulfiram (Antabuse): The Repurposed GSDMD Inhibitor¶

Disulfiram (brand name: Antabuse) is an FDA-approved drug prescribed to alcoholics as a deterrent — it causes severe flushing and illness if alcohol is consumed. In 2020, researchers discovered it has an entirely different and remarkable mechanism: direct gasdermin D inhibition at the final step of the NLRP3 inflammasome pathway.

This represents one of the most accessible, underrated, and economically efficient gout interventions available today.

Repurposing surface origin: Disulfiram is one of three concrete examples surfaced by the Open Enzyme discovery engine's chokepoint-to-FDA-drug mapping methodology — FDA-approved drugs that hit a gout chokepoint but were never clinically tested for gout. The other two are zileuton (CP6a 5-LOX, FDA-approved for asthma) and avacopan (CP0 C5aR1, FDA-approved for ANCA vasculitis). See open-enzyme-vision.md §2.2 for the full repurposing surface framing. (source: etc/open-enzyme-vision.md)

Compounding pharmacy delivery route: Disulfiram is the highest-priority candidate on the compounding pharmacy track — FDA-approved, off-patent, bulk API available, and the only barrier between the patient and a useful low-dose extended-release formulation is "no one has commercialized this specific formulation for gout." A compounded low-dose ER disulfiram tablet at sub-deterrent doses would allow exploring the GSDMD-inhibitor effect without the alcohol-flush mechanism dominating. (source: compounding-pharmacy-track.md)

Companion intervention: PDB-engineered EcN (urate-disposal upstream of NLRP3): Disulfiram closes the pyroptotic exit downstream of NLRP3, but does nothing to reduce the urate substrate that triggers NLRP3 in the first place. The natural companion is engineered E. coli Nissle expressing the purine-degrading-bacteria (PDB) gene cluster (CBT2.0 precedent, Li 2025, −63% plasma UA in mice) — drains luminal urate and produces butyrate → ABCG2 induction + NLRP3 dampening before MSU crystals seed an inflammasome. The two arms hit opposite ends of the urate→inflammation axis on completely separate chassis (engineered LBP vs. compounded small molecule), share no production or formulation stack, and stack additively. See purine-degrading-bacteria.md for the PDB mechanism and chassis-pending-interventions.md §"Multi-chassis stacks" M1 for the dual-arm framing. Computational priors completed 2026-05-16: comp-027 (disulfiram dose window → YELLOW-leaning-GREEN, 100 mg/day sub-AUD) + comp-031 (dual-chassis EcN additive SUA → YELLOW provisional, ~25–30% larger than PDB-alone). (source: disulfiram-dose-modeling-computational.md, dual-chassis-ecn-pdb-uricase-computational.md)

Complementary pharma at CP6: zileuton (5-LOX inhibitor, CP6a) and disulfiram (GSDMD inhibitor, CP6b) hit different branches of the same chokepoint. See wiki/zileuton.md for the CP6a pharma-grade option.

The GSDMD Target: Chokepoint 6b (Pyroptotic Exit)¶

In the NLRP3 inflammasome cascade, gasdermin D (GSDMD) is the "exit route" — the final executor that forms membrane pores and releases IL-1β into the extracellular space. Once IL-1β is outside the cell, it triggers the full inflammatory storm: neutrophil recruitment, pain, swelling, and the full gout flare symptomatology.

By blocking gasdermin D pore formation, disulfiram prevents IL-1β release without stopping the upstream inflammasome assembly.

(Source: nlrp3-exploit-map.md) — "Disulfiram — Antabuse — the drug prescribed to alcoholics since the 1950s — was discovered in 2020 (Nature Immunology) to specifically block gasdermin D pore formation at nanomolar concentrations. It covalently modifies Cys191 on GSDMD, preventing the N-terminal fragment from oligomerizing into membrane pores."

Mechanism: Covalent GSDMD Modification¶

The Chemistry¶

Disulfiram covalently modifies Cys191 (in humans; Cys192 in mice) on the gasdermin D protein. This modification prevents the processed N-terminal fragment of GSDMD from oligomerizing into the membrane-spanning pore structure required for IL-1β release.

Critically, disulfiram allows GSDMD cleavage by caspase-1 to proceed normally — it doesn't block the upstream inflammasome cascade. Instead, it blocks only the final pore-formation step.

(Source: nlrp3-exploit-map.md) — "The elegance: disulfiram still allows IL-1β and GSDMD processing (caspase-1 can still cleave them) but abrogates pore formation. No pores = IL-1β stays trapped inside the cell. No pores = no pyroptosis = no inflammatory amplification from cell death."

Alternative Modifications¶

Other compounds target the same Cys191 vulnerability:

DMF (Dimethyl Fumarate / Tecfidera): Succin ylates Cys191, forming S-(2-succinyl)-cysteine. FDA-approved for multiple sclerosis; discovered to block GSDMD as a mechanism
NSA: Research compound that modifies Cys191 via a different chemistry

The fact that multiple independent compounds converge on this single cysteine residue confirms it is a universal vulnerability.

Clinical Validation¶

The 2020 Discovery¶

Published in Nature Immunology (2020): researchers screened a library of FDA-approved drugs for NLRP3 pathway inhibition and found disulfiram's GSDMD-blocking activity. This wasn't a drug designed for this purpose — it was an accidental discovery during pharmacological screening.

Safety Profile: 70+ Years of Data¶

Disulfiram has been prescribed for alcohol use disorder since the 1950s. Decades of clinical experience demonstrate:

Excellent safety profile at standard doses (250 mg/day)
No hepatotoxicity (unlike MCC950, which caused liver failure in Phase 1 RA trials)
Well-characterized pharmacokinetics
Extensive understanding of drug interactions

This safety history means disulfiram can move directly to gout trials without extensive new safety work.

(Source: nlrp3-exploit-map.md) — "It's FDA-approved. It has 70+ years of safety data. It costs ~$30/month. You can get a prescription by... having a conversation with a doctor about alcohol use disorder, or by finding a physician interested in repurposed drug applications."

Economic Efficiency¶

This is the most cost-effective intervention in the entire gout pharmacopeia:

Drug	Mechanism	Annual Cost
Disulfiram	GSDMD inhibitor	~$120–360 (generic)
Colchicine	Microtubule/inflammasome	~$120–250
Allopurinol	Xanthine oxidase inhibitor	~$12–50
Pegloticase (IV)	Recombinant uricase	~$100,000+ per course
Dapansutrile (Phase 3)	NLRP3 inhibitor	Unknown (likely $200–500/month)
Canakinumab	Anti-IL-1β monoclonal	~$300,000/year (uninsured)

Disulfiram is not only effective but extraordinarily affordable, placing it in the same price tier as current standard-of-care flare prevention.

Practical Implementation¶

Getting a Prescription¶

Disulfiram requires a prescription. Access strategies:

Honest disclosure: Work with a physician on alcohol use — even patients with mild or history of alcohol issues can receive disulfiram for that indication
Repurposed indication: A rheumatologist or forward-thinking internist willing to prescribe off-label for gout given the GSDMD mechanism
Research enrollment: Some clinical trials may test disulfiram for gout

(Source: nlrp3-exploit-map.md) — "You can get a prescription by... having a conversation with a doctor about alcohol use disorder, or by finding a physician interested in repurposed drug applications. This is the single most accessible pharma-grade NLRP3 pathway exploit in this entire document."

Dosing¶

Standard (alcohol deterrent): 250 mg once daily, typically in the morning
Gout prophylaxis (sub-AUD GSDMD-dominant window): 100 mg/day (range 75–125 mg/day) — per comp-027 dose modeling (2026-05-16, YELLOW-leaning-GREEN). At 100 mg/day, parent DSF Cmax (0.40 µM) engages GSDMD pore-formation blockade at 1.3× cell-free IC50 (0.30 µM per Hu 2020) while plasma Me-DTC peak (~70 nM) stays at or below the Faiman-1989 DER hypotension threshold (~70 nM at 40% ALDH inhibition). NLRP3-palmitoylation EC50 (Xu 2024, 10 µM) requires AUD-dose+ plasma — sub-AUD is selectively GSDMD-engaging, not pan-NLRP3-engaging. Two-phase compounding protocol: IR capsule 50→100 mg/d titration over 14 days, then ER lipid-matrix 100 mg QD chronic. (Mechanistic Extrapolation + In Silico; source: disulfiram-dose-modeling-computational.md)
Acute flare: Unclear; probably prophylactic use rather than acute dosing

Safety Considerations¶

Alcohol interaction: Disulfiram blocks aldehyde dehydrogenase, causing severe flushing, nausea, and cardiovascular stress if alcohol is consumed. This is intentional for alcohol-use deterrence but requires absolute abstinence
Copper chelation: Disulfiram binds copper; patients on copper-dependent enzyme therapies (e.g., [[gotu-kola|GHK-Cu peptide]]) may experience reduced efficacy
Drug interactions: Check for interactions with anticoagulants and other medications

Expanded Contraindications and Drug Interactions (source: supplements-stack.md, 2026-04-26)¶

Contraindications: - Any alcohol use (acute disulfiram-ethanol reaction: flushing, tachycardia, hypotension, severe nausea — can be fatal at high alcohol doses). This includes some mouthwashes, OTC cold preparations, kombucha, and fermented foods with residual ethanol. - Active hepatic disease (LFTs >3× upper limit of normal) - Severe coronary artery disease (cardiovascular collapse risk on ethanol exposure) - Severe psychosis (case reports of psychotic exacerbation) - Pregnancy - Concurrent metronidazole or other disulfiram-like agents

Drug interactions: - Metronidazole, tinidazole, cefoperazone, griseofulvin, certain MAOIs, isoniazid: disulfiram-like reactions amplified. - Warfarin: disulfiram inhibits warfarin metabolism → increased anticoagulation; INR monitoring required. - Phenytoin: disulfiram inhibits phenytoin metabolism → toxicity risk. - Theophylline, caffeine (high-dose): disulfiram inhibits clearance; toxicity risk. - Benzodiazepines metabolized by CYP3A4 (alprazolam, midazolam): disulfiram inhibits clearance; sedation risk. - Acetaminophen at high doses: competing hepatic stress (additive hepatotoxicity). - Many ethanol-containing medications (some elixirs, sublingual sprays, IV preparations): trigger reaction.

Dose-dependent risk profile: - 250 mg/day (standard): well-tolerated in alcohol-abstinent patients. Hepatotoxicity (idiosyncratic) is the main rare serious side effect; baseline + periodic LFTs recommended. - 500 mg/day (historical dose, less common now): more side effects (drowsiness, peripheral neuropathy, hepatic stress) without proportional efficacy gain. - Disulfiram-ethanol reaction severity scales with both disulfiram dose and ethanol exposure.

Stack-level safety note — fermented foods: - Kombucha and koji-fermented foods may contain residual ethanol that could trigger reaction in disulfiram-sensitive patients. Practical limit: dietary intake of well-fermented foods at typical portion sizes is generally below the threshold but is patient-specific. Disulfiram users should avoid kombucha entirely and treat any koji-derived fermented foods as a per-batch ethanol-content question. - Home-fermented amazake / shio-koji: wild-yeast contamination of a "failed" batch can push residual ethanol to 1–3% v/v. Disulfiram users running the koji home-fermentation protocol should pre-screen every finished batch with consumer ethanol test strips (~$15, ±0.1% v/v) before consumption and discard any batch reading >0.1%. Do not rely on cook-off / volatilization — see the "Drug-interaction warning" subsection in koji-home-fermentation.md for the routine precaution. (source: koji-home-fermentation.md) - Hepatotoxicity stacking concern with EGCG, high-dose curcumin, acetaminophen: all four contribute to hepatic stress; layering is a relative contraindication.

(source: supplements-stack.md)

Comparison: Disulfiram vs. Other Inflammasome Inhibitors¶

Drug	Chokepoint	Class	Status	Cost	Safety Data
Disulfiram	6b (GSDMD pore)	Approved (Rx)	Widely available	~$30/month	70+ years
Zileuton	6a (5-LOX/LTB4)	Approved (Rx, asthma)	Available; off-label in gout	~$50/month generic	30+ years (asthma)
DMF	6b (GSDMD)	Approved (MS)	Requires MS diagnosis	High	15+ years (MS)
Dapansutrile	2 (NLRP3)	Phase 3 clinical	Investigational	Unknown	<5 years
Oridonin	1, 2	Natural/research	Preclinical	~$30/month	Unknown human data
Colchicine	3 (ASC/microtubule)	Approved (Rx)	Standard of care	~$20/month	50+ years

Key insight: Disulfiram is the only GSDMD inhibitor with both FDA approval and extensive clinical safety history. It's a uniquely accessible entry point to inflammasome modulation.

The Black Hat Insight¶

(Source: nlrp3-exploit-map.md) — "This is the black hat's dream exploit. Disulfiram — Antabuse — the drug prescribed to alcoholics since the 1950s — was discovered in 2020 (Nature Immunology) to specifically block gasdermin D pore formation at nanomolar concentrations... It's FDA-approved. It has 70+ years of safety data. It costs ~$30/month."

Disulfiram represents a market inefficiency in medical knowledge: rheumatologists and immunologists know about NLRP3 inhibitors and GSDMD as a target, but gout specialists have not widely integrated this discovery into clinical practice. This is an underutilized tool that could be deployed immediately.

Integration with Multi-Attack Strategy¶

In the context of comprehensive gout management:

Remove the cause: [[engineered-koji|Engineered koji]] or [[engineered-yeast|yeast expressing uricase]] address the underlying uric acid burden
Defuse the bomb (upstream): [[bhb-ketones|BHB]], [[kpv-peptide|KPV]], [[oridonin|oridonin]] suppress NLRP3 priming and assembly
Defuse the bomb (downstream): Disulfiram blocks the final IL-1β release step
Heal the damage: [[peptide-therapy|BPC-157, TB-500]] for tissue repair

Disulfiram provides a simple, affordable, well-tolerated entry point to the NLRP3 pharmacological toolkit.

[[nlrp3-inflammasome|NLRP3 Inflammasome]] — The general pathway
[[gasdermin-d|Gasdermin D]] — The specific target
[[gout|Gout Flare Cascade]] — The disease mechanism
[[dapansutrile|Dapansutrile (OLT1177)]] — The Phase 3 NLRP3 inhibitor

Key Insight¶

Disulfiram is the most economically efficient, safest, and most accessible gout pharmacotherapy targeting the NLRP3 inflammasome. It blocks IL-1β release at the final step, preventing the inflammatory amplification that causes pain. It costs ~$30/month, has 70 years of safety data, and is available immediately with a prescription. The limitation is awareness — this repurposed drug has not yet entered rheumatology practice for gout, despite strong mechanistic rationale and exceptional economic and safety characteristics.

Last updated: April 2026 Wiki synthesized from primary research documents